Apellis amends executive separation plan to accelerate vesting on termination pre-close

• Apellis Pharmaceuticals compensation committee set amendment and restatement of Executive Separation Benefits and Retention Plan, tied to merger agreement with Biogen.
• Plan becomes effective on closing date of transaction.
• Unvested rights to payments for Converted Options and Converted RSU Awards would accelerate and fully vest if participant is terminated without cause or resigns for good reason before vesting.
• Good Reason definition change removes carve-out for post-merger scope changes for C-level officers, including named executive officers.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Apellis Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-202504), on May 04, 2026, and is solely responsible for the information contained therein.